Enhanced Genomics has appointed Katerina Leftheris, PhD, to its board of directors as part of its strategy to expand its internal therapeutics pipeline.

Leftheris brings more than 30 years of experience in senior scientific roles across pharma and MedTech, including at Bristol Myers Squibb, Celgene and Pliant Therapeutics, where she helped advance 15 compounds into clinical development.

Most recently, she served as chief scientific officer at machine learning-driven drug developer Vilya and sits on multiple boards and advisory panels.

Her expertise in medicinal chemistry and drug discovery will support the development of therapies identified using Enhanced’s 3D multi-omics GenLink platform.